Subscribe to RSS
Can Routine Blood Biochemistry Parameters be Predictive Prognostic Marker(s) in Operated Patients with Meningioma WHO Grade 1?
Background Today, there is a need for new and independent additional advanced markers that can predict the prognosis of meningioma patients, postoperatively. The present study aimed to find out postoperative short-term prognostic markers in patients with meningioma using their demographic data and routine blood biochemistry findings evaluated preoperatively.
Methods The Glasgow Coma Scale (GCS), and Glasgow Outcome Scale (GOS) scores of the patients were recorded. Additionally, preoperatively obtained serum glucose, C-reactive protein (CRP), sodium, potassium, creatinine, blood urea nitrogen, aspartate aminotransferase (AST), alanine aminotransferase, and hemoglobin level values, platelet, leukocyte, neutrophil, lymphocyte, eosinophil, basophil, and monocyte count results, erythrocyte sedimentation rate (ESR), neutrophil-lymphocyte ratio, platelet-lymphocyte ratio (PLR) and lymphocyte-monocyte ratio (LMR) values were evaluated.
Results In the present study, 23 operated patients with meningioma World Health Organization (WHO) grade 1 (17 females, 6 males) were included. Correlation test results revealed that the GCS score, platelet count, and serum potassium level values could directly predict the short-term prognosis of these patients. Additionally, these test results suggested that the lymphocyte, monocyte, and eosinophil count values, PLR, LMR, ESR, serum glucose, CRP, and AST level values could be indirect markers in predicting the short-term prognosis. However, likelihood ratio test results revealed that only monocyte count value, LMR value, and serum CRP level value could be the markers for prediction of the short-term prognosis.
Conclusion At the end of the present study, it was concluded that the monocyte count value, LMR value, and serum CRP level value could be the best markers in predicting the short-term prognosis of the operated meningioma patients.
Financial Disclosure Statements
The authors declare that they have not engaged in any financial relationship with any company whose product might be affected by the research described or with any company that makes or markets a competing product.
Since the present study had a retrospective character, the patients were informed that their information could be used in the study on the condition of protecting their personal information, and consent was obtained, so no additional consent was obtained.
Received: 08 August 2020
Accepted: 16 November 2020
18 January 2021 (online)
© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
- 1 Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12 (04) 253-268 DOI: 10.1038/nri3175.
- 2 Mueller MM, Fusenig NE. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004; 4 (11) 839-849 DOI: 10.1038/nrc1477.
- 3 Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol 2014; 15 (11) e493-e503 DOI: 10.1016/S1470-2045(14)70263-3.
- 4 Nijaguna MB, Schröder C, Patil V. et al. Definition of a serum marker panel for glioblastoma discrimination and identification of Interleukin 1β in the microglial secretome as a novel mediator of endothelial cell survival induced by C-reactive protein. J Proteomics 2015; 128: 251-261 DOI: 10.1016/j.jprot.2015.07.026.
- 5 van Alkemade H, de Leau M, Dieleman EM. et al. Impaired survival and long-term neurological problems in benign meningioma.. Neuro Oncol 2012; 14 (05) 658-666 DOI: 10.1093/neuonc/nos013.
- 6 Bunevicius A, Radziunas A, Tamasauskas S. et al. Prognostic role of high sensitivity C-reactive protein and interleukin-6 in glioma and meningioma patients. J Neurooncol 2018; 138 (02) 351-358 DOI: 10.1007/s11060-018-2803-y.
- 7 Park KJ, Kang SH, Chae YS. et al. Influence of interleukin-6 on the development of peritumoral brain edema in meningiomas. J Neurosurg 2010; 112 (01) 73-80 DOI: 10.3171/2009.4.JNS09158.
- 8 Strojnik T, Smigoc T, Lah TT. Prognostic value of erythrocyte sedimentation rate and C-reactive protein in the blood of patients with glioma. Anticancer Res 2014; 34 (01) 339-347
- 9 Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale. Lancet 1974; 2 (7872): 81-84
- 10 McMillan T, Wilson L, Ponsford J, Levin H, Teasdale G, Bond M. The Glasgow Outcome Scale - 40 years of application and refinement. Nat Rev Neurol 2016; 12 (08) 477-485 DOI: 10.1038/nrneurol.2016.89.
- 11 Helmersson-Karlqvist J, Flodin M, Havelka AM, Xu XY, Larsson A. The Roche Immunoturbidimetric Albumin Method on Cobas c 501 Gives Higher Values Than the Abbott and Roche BCP Methods When Analyzing Patient Plasma Samples. J Clin Lab Anal 2016; 30 (05) 677-681 DOI: 10.1002/jcla.21921.
- 12 Fogh-Andersen N, Wimberley PD, Thode J, Siggaard-Andersen O. Determination of sodium and potassium with ion-selective electrodes. Clin Chem 1984; 30 (03) 433-436
- 13 Khayat Kashani HR, Azhari S, Nayebaghayee H, Salimi S, Mohammadi HR. Prediction value of preoperative findings on meningioma grading using artificial neural network. Clin Neurol Neurosurg 2020; 196: 105947 DOI: 10.1016/j.clineuro.2020.105947.
- 14 Chaturvedi AK, Caporaso NE, Katki HA. et al. C-reactive protein and risk of lung cancer. J Clin Oncol 2010; 28 (16) 2719-2726 DOI: 10.1200/JCO.2009.27.0454.
- 15 Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA 2004; 291 (05) 585-590 DOI: 10.1001/jama.291.5.585.
- 16 Juan H, Qijun W, Junlan L. Serum CRP protein as a differential marker in cancer. Cell Biochem Biophys 2012; 64 (02) 89-93 DOI: 10.1007/s12013-012-9375-9.
- 17 Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009; 30 (07) 1073-1081 DOI: 10.1093/carcin/bgp127.
- 18 Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420 (6917): 860-867 DOI: 10.1038/nature01322.
- 19 Heikkilä K, Ebrahim S, Lawlor DA. A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health 2007; 61 (09) 824-833 DOI: 10.1136/jech.2006.051292.
- 20 Cheng H, Long F, Jaiswar M, Yang L, Wang C, Zhou Z. Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: a meta-analysis. Sci Rep 2015; 5: 11026 DOI: 10.1038/srep11026.
- 21 Shirai Y, Shiba H, Sakamoto T. et al. Preoperative platelet to lymphocyte ratio predicts outcome of patients with pancreatic ductal adenocarcinoma after pancreatic resection. Surgery 2015; 158 (02) 360-365 DOI: 10.1016/j.surg.2015.03.043.
- 22 Stotz M, Gerger A, Eisner F. et al. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer 2013; 109 (02) 416-421 DOI: 10.1038/bjc.2013.332.
- 23 Szkandera J, Gerger A, Liegl-Atzwanger B. et al. The lymphocyte/monocyte ratio predicts poor clinical outcome and improves the predictive accuracy in patients with soft tissue sarcomas. Int J Cancer 2014; 135 (02) 362-370 DOI: 10.1002/ijc.28677.
- 24 Qi Q, Zhuang L, Shen Y. et al. A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. Cancer 2016; 122 (14) 2158-2167 DOI: 10.1002/cncr.30057.
- 25 Liang RF, Li M, Li JH, Zuo MR, Yang Y, Liu YH. The significance of preoperative hematological inflammatory markers in patients with meningiomas. Clin Neurol Neurosurg 2019; 182: 1-4 DOI: 10.1016/j.clineuro.2019.04.020.
- 26 Xu L, Yu S, Zhuang L. et al. Systemic inflammation response index (SIRI) predicts prognosis in hepatocellular carcinoma patients. Oncotarget 2017; 8 (21) 34954-34960 DOI: 10.18632/oncotarget.16865.
- 27 Kataki A, Skandami V, Memos N. et al. Similar immunity profiles in patients with meningioma and glioma tumors despite differences in the apoptosis and necrosis of circulating lymphocyte and monocyte populations. J Neurosurg Sci 2014; 58 (01) 9-15